February 25, 2026 – Nashville, Tennessee, USA
OneOncology has announced that its Oncology Quality Hub has been officially approved by the Centers for Medicare & Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) for 2026, marking the second consecutive year the physician-led national oncology platform has secured the federal designation. The approval underscores the organization’s continued ability to meet rigorous CMS standards for collecting, analyzing, and reporting clinical outcomes data on behalf of oncology providers participating in the Quality Payment Program (QPP) and the Merit-based Incentive Payment System (MIPS). The recognition reflects OneOncology’s growing influence in advancing real-world oncology data infrastructure, performance benchmarking, and value-based cancer care delivery across the United States.
Strengthening Agricultural Heritage and Community Economy
As a CMS-approved QCDR, OneOncology is authorized to aggregate and submit clinical performance data from its partner practices through multiple electronic medical record (EMR) systems. This capability enables oncology providers to streamline quality reporting while improving accuracy, compliance, and administrative efficiency. By centralizing oncology-specific data capture, the Oncology Quality Hub supports physicians in optimizing MIPS performance scores, reducing reporting burden, and aligning clinical workflows with federal reimbursement requirements.
The registry framework allows practices to report specialty-focused quality metrics that better reflect real-world oncology care delivery compared to generalized reporting systems. Through its infrastructure, OneOncology facilitates performance tracking across medical oncology, radiation oncology, and urology practices, reinforcing integrated specialty care models while enabling clinicians to meet evolving CMS compliance benchmarks.
Introducing DPYD Screening Quality Measure
Advertisement
A significant advancement accompanying the 2026 designation is CMS approval of a newly developed oncology-specific quality measure introduced by OneOncology: DPYD (dihydropyrimidine dehydrogenase) screening. This pharmacogenomic test identifies patients who may be at heightened risk for severe toxicity when treated with fluoropyrimidine chemotherapy agents.
DPYD enzyme deficiency can lead to life-threatening adverse reactions if undetected prior to treatment. By embedding DPYD screening into quality reporting metrics, OneOncology is promoting personalized oncology treatment planning, improved patient safety, and proactive toxicity prevention.
The measure aligns with updated national guidance from leading regulatory and clinical bodies, reinforcing the importance of genetic testing integration into routine oncology workflows. Early adoption and CMS approval of the screening metric demonstrate the organization’s responsiveness to evolving standards of care and its commitment to embedding precision medicine principles into quality frameworks.
Advancing Value-Based Cancer Care Delivery
OneOncology leadership emphasized that continued CMS recognition validates the platform’s role in enabling independent oncology practices to thrive within value-based reimbursement environments. By leveraging deep expertise in federal reporting programs, the organization supports partner clinics in achieving regulatory compliance while maintaining patient-centered care delivery.
Through the Oncology Quality Hub, participating providers gain access to actionable analytics, benchmarking insights, and workflow optimization tools designed to enhance treatment outcomes and operational performance. The platform’s expansion also reflects broader healthcare industry momentum toward real-world evidence generation, data-driven oncology care models, and outcomes-based reimbursement structures.
As oncology continues to evolve toward integrated specialty collaboration, data registries like OneOncology’s QCDR serve as foundational infrastructure supporting clinical excellence, regulatory alignment, and measurable quality improvement across cancer treatment networks.
Source: OneOncology press release
